What is United Therapeutics Debt-to-Equity?
United Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $300 Mil. United Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0 Mil. United Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $6,444 Mil.
United Therapeutics's debt to equity for the quarter that ended in Dec. 2024 was 0.05.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for United Therapeutics's Debt-to-Equity or its related term are showing as below:
UTHR'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.14 Max: 0.31
Current: 0.05
During the past 13 years, the highest Debt-to-Equity Ratio of United Therapeutics was 0.31. The lowest was 0.05. And the median was 0.14.
United Therapeutics Debt-to-Equity Historical Data
The historical data trend for United Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics Debt-to-Equity Chart
|
United Therapeutics Annual Data
|
|
Trend |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
Dec24 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
|
|
0.24 |
0.20 |
0.17 |
0.12 |
0.05 |
|
United Therapeutics Quarterly Data
|
|
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
Jun24 |
Sep24 |
Dec24 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.12 |
0.11 |
0.09 |
0.07 |
0.05 |
Competitive Comparison of United Therapeutics's Debt-to-Equity
For the Biotechnology subindustry, United Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, United Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where United Therapeutics's Debt-to-Equity falls into.
United Therapeutics Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
United Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as
United Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics Business Description
Traded in Other Exchanges
Address
1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Executives
| Christopher Patusky |
director |
|
| Michael Benkowitz |
officer: President and COO |
C/O UNITED THERAPEUTICS CORP, 1040 SPRING STREET, SILVER SPRING MD 20910 |
| Tommy G Thompson |
director |
7711 CARONDELET, ST. LOUIS MO 63105 |
| Ray Kurzweil |
director |
|
| Nilda Mesa |
director |
C/O UNITED THERAPEUTICS CORPORATION, 1040 SPRING STREET, SILVER SPRING MD 20910 |
| Louis W Sullivan |
director |
|
| Paul A Mahon |
officer: EVP & General Counsel |
|
| Judy D. Olian |
director |
2000 AVENUE OF THE STARS 12TH FL, LOS ANGELES CA 90067 |
| Richard Giltner |
director |
C/O UNITED THERAPEUTICS CORPORTION, 1735 CONNECTICUT AVE. NW, WASHINGTON DC 20009 |
| James Edgemond |
officer: CFO and Treasurer |
1040 SPRING STREET, SILVER SPRING MD 20910 |
| Christopher Causey |
director |
|
| Martine A Rothblatt |
director, officer: Chief Executive Officer |
|
| Raymond Dwek |
director |
|
| Linda Maxwell |
director |
1040 SPRING STREET, SILVER SPRING NC 27709 |
| Katherine J Klein |
director |
STEINBERG HALL-DIETRICH HALL, 3620 LOCUST WALK, PHILADELPHIA PA 19104 |
United Therapeutics Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
UTHR has been successfully added to your